Aldolase B Deficient Mice Are Characterized by Hepatic Nucleotide Sugar Abnormalities

Abstract

Hereditary fructose intolerance (HFI) is characterized by liver damage and a secondary defect in N‐linked glycosylation due to impairment of mannose phosphate isomerase (MPI). Mannose treatment has been shown to be an effective treatment in a primary defect in MPI (i.e., MPI‐CDG), which is also characterized by liver damage. Therefore, the aims of this study were to determine: (1) hepatic nucleotide sugar levels, and (2), the effect of mannose supplementation on hepatic nucleotide sugar levels and liver fat, in a mouse model for HFI. Aldolase B deficient mice (Aldob−/−) were treated for four weeks with 5% mannose via the drinking water and compared to Aldob−/− mice and wildtype mice treated with regular drinking water. We found that hepatic GDP‐mannose and hepatic GDP‐fucose were lower in water‐treated Aldob−/− mice when compared to water‐treated wildtype mice (p = 0.002 and p = 0.002, respectively), consistent with impaired N‐linked glycosylation. Of interest, multiple other hepatic nucleotide sugars not involved in N‐linked glycosylation, such as hepatic UDP‐glucuronic acid, UDP‐xylose, CMP‐N‐acetyl‐beta‐neuraminic acid, and CDP‐ribitol (p = 0.002, p = 0.003, p = 0.002, p = 0.002), were found to have altered levels as well. However, mannose treatment did not correct the reduction in hepatic GDP‐mannose levels, nor was liver fat affected. Aldob−/− mice are characterized by hepatic nucleotide sugar abnormalities, but these were not abrogated by mannose treatment. Future studies are needed to identify the underlying mechanisms responsible for the abnormal hepatic nucleotide sugar pattern and intrahepatic lipid accumulation in HFI.Trial Registration: PCT ID: PCTE0000340, this animal experiment is registered at (https://preclinicaltrials.eu/).